Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic Mice

Hyperuricemia (HUA) is a metabolic disease characterized by elevated serum uric acid (SUA). Empagliflozin, a kind of sodium-glucose cotransporter 2 inhibitors, has recently emerged as a new antidiabetic agent by facilitating glucose excretion in urine. Moreover, there was evidence of SUA reduction f...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yun-hong, Chang, Yun-peng, Li, Ting, Han, Fei, Li, Chun-jun, Li, Xiao-yu, Xue, Mei, Cheng, Ying, Meng, Zi-yu, Han, Zhe, Sun, Bei, Chen, Li-ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990905/
https://www.ncbi.nlm.nih.gov/pubmed/32015688
http://dx.doi.org/10.7150/ijbs.33007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990905/
https://www.ncbi.nlm.nih.gov/pubmed/32015688
http://dx.doi.org/10.7150/ijbs.33007

Ejemplares similares